Loading...

MedXY News - Alzheimer's disease

MedXY AI/MedXY News/Tag: Alzheimer's disease

MedXY News

EnglishTag

Alzheimer's disease

67 all articles · 20 / page

Ask MedXY AI

clinical trial type 2 diabetes heart failure immunotherapy obesity atrial fibrillation Cardiology oncology cardiovascular risk biomarkers clinical trials public health Hypertension critical care breast cancer artificial intelligence Alzheimer's disease diabetes nutrition chronic kidney disease cardiovascular disease Pediatrics

Latest news

Tag

Identification of Genetic Modifiers of Autosomal Dominant Alzheimer’s Disease: A Genome-Wide Association Study

Identification of Genetic Modifiers of Autosomal Dominant Alzheimer’s Disease: A Genome-Wide Association Study

A genome-wide study identified three genetic modifiers of autosomal dominant Alzheimer’s disease, linking them to disease risk, earlier onset, and biomarker changes involving amyloid, tau, TDP-43, and brain aging.

Section: NeurologyJun 10, 2026

Women’s Elevated P-Tau217 Levels and Faster Cognitive Decline: Implications for Preclinical Alzheimer’s Disease

Women’s Elevated P-Tau217 Levels and Faster Cognitive Decline: Implications for Preclinical Alzheimer’s Disease

Women with high amyloid-β show higher p-tau217 levels and faster tau accumulation than men, leading to greater cognitive decline. This sex-specific tau response may redefine preclinical Alzheimer’s diagnostics and therapeutics.

Section: NeurologyMay 1, 2026

Sex-Specific Differences in P-Tau217 and Tau Aggregation: Implications for Preclinical Alzheimer’s Disease

Sex-Specific Differences in P-Tau217 and Tau Aggregation: Implications for Preclinical Alzheimer’s Disease

Women exhibit higher plasma p-tau217 levels and tau aggregation than men in amyloid-positive individuals, suggesting sex-specific pathways in Alzheimer’s disease progression.

Section: NeurologyMay 1, 2026

Precision Blood-Based Diagnostics for Alzheimer’s Disease: The Synergistic Role of Plasma p-tau217 and eMTBR-tau243

Precision Blood-Based Diagnostics for Alzheimer’s Disease: The Synergistic Role of Plasma p-tau217 and eMTBR-tau243

This review synthesizes recent clinical evidence on the integration of plasma p-tau217 and eMTBR-tau243, highlighting how sequential biomarker testing improves the diagnosis of symptomatic Alzheimer’s disease and predicts longitudinal cogni

Section: Clinical UpdatesApr 10, 2026

Beyond Aging: Traumatic Brain Injury and Depression Emerge as Leading Predictors of Dementia in US Veterans

Beyond Aging: Traumatic Brain Injury and Depression Emerge as Leading Predictors of Dementia in US Veterans

A large-scale analysis of the VA Million Veteran Program reveals that TBI, depression, and specific military environmental exposures significantly elevate the 10-year risk of Alzheimer’s and related dementias, highlighting critical targets

Section: NeurologyMar 13, 2026

Precision Diagnostics in Alzheimer’s Disease: Optimizing Plasma p-tau217 Cutoffs for Patients with Comorbidities

Precision Diagnostics in Alzheimer’s Disease: Optimizing Plasma p-tau217 Cutoffs for Patients with Comorbidities

This review synthesizes evidence on the impact of kidney function, BMI, and anemia on plasma p-tau217 diagnostic accuracy, advocating for subgroup-specific cutoff strategies to improve clinical outcomes.

Section: Clinical UpdatesMar 10, 2026

Dual-Pathology Burden: How Comorbid Alzheimer’s and FTLD Drive Distinct Neuropsychiatric Phenotypes

Dual-Pathology Burden: How Comorbid Alzheimer’s and FTLD Drive Distinct Neuropsychiatric Phenotypes

This study highlights how comorbid Alzheimer’s and FTLD neuropathologies manifest through unique neuropsychiatric profiles, such as increased anxiety and personality changes, providing clinicians with vital clues for identifying mixed neuro

Section: NeurologyMar 9, 2026

Evaluating Low-Dose Lithium Carbonate for the Management of Mild Cognitive Impairment: A 2-Year Randomized Pilot Study

Evaluating Low-Dose Lithium Carbonate for the Management of Mild Cognitive Impairment: A 2-Year Randomized Pilot Study

This pilot randomized clinical trial investigated low-dose lithium for Mild Cognitive Impairment (MCI). While primary outcomes regarding cognition and neuroimaging were not statistically significant, the study established the intervention’s

Section: NeurologyMar 3, 2026

Sex-Specific P-Tau217 Dynamics: Why Women Exhibit Accelerated Tau Accumulation and Cognitive Decline

Sex-Specific P-Tau217 Dynamics: Why Women Exhibit Accelerated Tau Accumulation and Cognitive Decline

A multi-cohort study demonstrates that women with amyloid-β pathology show higher plasma p-tau217 levels and faster tau PET accumulation than men, providing a biological basis for their increased risk of rapid cognitive decline in preclinic

Section: NeurologyFeb 20, 2026

The Landscape of Late-Life Dementia: Why Mixed Neuropathologies Are the Rule, Not the Exception

The Landscape of Late-Life Dementia: Why Mixed Neuropathologies Are the Rule, Not the Exception

A large-scale longitudinal study reveals that over 80% of community-dwelling older adults harbor mixed neuropathologies, identifying five distinct profiles that dictate specific cognitive decline trajectories, with ADNC and LATE-NC clusters

Section: NeurologyFeb 12, 2026

Biologically Informed p-tau217 Cutoffs: Refining Alzheimer’s Diagnosis Across Diverse Patient Profiles

Biologically Informed p-tau217 Cutoffs: Refining Alzheimer’s Diagnosis Across Diverse Patient Profiles

Standard single cutoffs for plasma p-tau217 are significantly confounded by kidney function, BMI, and anemia. A new study demonstrates that subgroup-specific or double-cutoff strategies markedly improve diagnostic accuracy and cost-effectiv

Section: NeurologyFeb 7, 2026

Liraglutide and Alzheimer’s Disease: Can GLP-1 Agonists Bridge the Metabolic-Cognitive Gap?

Liraglutide and Alzheimer’s Disease: Can GLP-1 Agonists Bridge the Metabolic-Cognitive Gap?

The Phase 2b ELAD trial investigated liraglutide’s efficacy in mild-to-moderate Alzheimer’s disease. While it failed its primary metabolic endpoint, significant improvements in executive function suggest a nuanced role for GLP-1 agonists in

Section: Diabetes & EndocrinologyFeb 4, 2026

Tau Pathology Acts as a Switch: How Soluble Amyloid Drives Early Metabolic and Neuropsychiatric Symptoms in Alzheimer’s Disease

Tau Pathology Acts as a Switch: How Soluble Amyloid Drives Early Metabolic and Neuropsychiatric Symptoms in Alzheimer’s Disease

Recent clinical evidence reveals that soluble amyloid-beta oligomers, rather than traditional plaques, drive glucose dysregulation and depression in early Alzheimer’s disease. Crucially, these associations are modulated by tau pathology, su

Section: NeurologyFeb 3, 2026

Crenezumab Fails to Meet Primary Endpoints in Preclinical Autosomal-Dominant Alzheimer’s: Insights from the API ADAD Colombia Trial

Crenezumab Fails to Meet Primary Endpoints in Preclinical Autosomal-Dominant Alzheimer’s: Insights from the API ADAD Colombia Trial

A Phase 2 trial of crenezumab in cognitively unimpaired PSEN1 mutation carriers found no significant clinical benefit over 5-8 years, suggesting that robust amyloid plaque removal may be essential for disease modification in early-stage Alz

Section: NeurologyJan 29, 2026

Oligodendrocyte Myelin Glycoprotein: A Novel Plasma Determinant of Neurodegenerative Resiliency

Oligodendrocyte Myelin Glycoprotein: A Novel Plasma Determinant of Neurodegenerative Resiliency

A comprehensive multi-cohort proteomic study identifies Oligodendrocyte Myelin Glycoprotein (OMG) as a causal biomarker for neurodegenerative resiliency, linking its peripheral abundance to axonal integrity and reduced risk of dementia and

Section: NeurologyJan 7, 2026

Age and Sex Redefine the Amyloid-to-Tau Transition: Establishing Patient-Centered PET Thresholds for Alzheimer’s Disease

Age and Sex Redefine the Amyloid-to-Tau Transition: Establishing Patient-Centered PET Thresholds for Alzheimer’s Disease

This study establishes patient-centered amyloid PET thresholds for tauopathy onset, revealing that age and sex significantly influence the transition from amyloidosis to tau accumulation. These personalized cut-offs better predict cognitive

Section: NeurologyJan 7, 2026

Significant 1-Year Risk of Cardiovascular Events in Cognitive Impairment Highlights Safety Concerns for Anti-Amyloid Therapy

Significant 1-Year Risk of Cardiovascular Events in Cognitive Impairment Highlights Safety Concerns for Anti-Amyloid Therapy

A longitudinal study reveals that over 5% of patients with MCI or dementia develop new indications for anticoagulants or thrombolytics within a year, complicating the use of anti-amyloid monoclonal antibodies due to increased intracranial h

Section: CardiologyJan 7, 2026

Beyond the Lungs: How Ambient Air Pollution Drives Alzheimer’s Neuropathology and Cognitive Decline

Beyond the Lungs: How Ambient Air Pollution Drives Alzheimer’s Neuropathology and Cognitive Decline

Emerging evidence confirms that air pollution, particularly PM2.5 and NO2, is directly associated with Alzheimer’s neuropathology, structural brain changes, and cognitive decline. New research highlights that these effects are partially med

Section: NeurologyJan 2, 2026

Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

Predicting Alzheimer’s Progression: The Power of Tau-Clinical Mismatch in Identifying Copathology and Resilience

This study demonstrates that the mismatch between tau burden and clinical symptoms identifies individuals with non-AD copathology or cognitive resilience. These findings offer a precision medicine framework for predicting disease trajectori

Section: NeurologyDec 27, 2025

Blarcamesine in Early Alzheimer’s Disease: Promising Results Amidst Controversies

Blarcamesine in Early Alzheimer’s Disease: Promising Results Amidst Controversies

Blarcamesine shows potential in slowing early Alzheimer’s progression, but questions about trial data robustness and transparency have been raised.

Section: Internal MedicineDec 25, 2025

Prev 1 2 3 4 Next